Molecular Profiling to Guide Fertility Sparing Therapy in Early-Stage Endometrial Cancer: A EORTC Gynaecological Cancer Group Study
Authors:
- Ramon YarzaRYRamon Yarza
- Reyes Oliver-PérezROReyes Oliver-Pérez
- Eva OldenburgerEva Oldenburger
- Lawrence KashermanLKLawrence Kasherman
- Shira Peleg HassonSHShira Peleg Hasson
- José Manuel Estrada-LorenzoJEJosé Manuel Estrada-Lorenzo
- Beatriz Álvarez-RodríguezBÁBeatriz Álvarez-Rodríguez
- Alberto Martinez de LaraALAlberto Martinez de Lara
- Fernanda HerreraFHFernanda Herrera
- Judith KroepJudith Kroep
- Ainhoa MadariagaAMAinhoa Madariaga
Open Access
Abstract
Objective: Fertility-preserving therapies are a potential option for selected patients with early-stage endometrial cancer and atypical endometrial hyperplasia/endometrial intraepithelial neoplasia. This systematic review aims to evaluate the impact of fertility-preserving strategies according to molecular subtype. Methods: A comprehensive search was conducted in PubMed, Cochrane Library, EMBASE, and Web of Science for English-language studies published until June 2024, investigating fertility-sparing treatments using endocrine therapy in early-stage endometrial cancer, considering molecular classification. The PRISMA checklist was followed, and the protocol was registered in PROSPERO (CRD42025649342). Data on body mass index (BMI), age, and molecular classification (POLE-mutant, non-specific molecular profile [NSMP], p53-abnormal, and mismatch repair deficient [dMMR]) were extracted. The study assessed objective response rates (ORR), pregnancy outcomes, and survival outcomes. Statistical analyses were performed using R software. Results: The search identified 941 articles, and 10 studies with 457 patients were selected for final analysis. Pregnancy outcomes were reported in three studies, whilst all reported ORR data. Baseline median age (dMMR 35 years, POLE-mutant 38.2 years, p53-abnormal 33.9 years, and NSMP 31.6 years) and BMI (dMMR 24.3, POLE-mutant 27.9, p53-abnormal 26.2, and NSMP 29.8) differed by molecular subtype. Aggregated full-term delivery rates from the three studies reporting pregnancy outcomes were 36.4% (4/11) for POLE-mutant, 22.1% (27/122) for NSMP, 14.3% (1/7) for p53-abnormal, and 4.0% (1/25) for dMMR tumours, but statistical comparison was not feasible due to small sample size. Overall response rate was highest in NSMP (87.4%) and POLE-mutant tumours (84.6%), while dMMR (59.3%) and p53-abnormal (58.8%) had significantly lower ORR (compared to NSMP, p < 0.001 and p = 0.03, respectively). Conclusions: These findings support the potential role of molecular classification in refining patient selection for fertility-sparing treatment in early-stage endometrial cancer. Pregnancy-related outcomes should be interpreted with caution given the limited available evidence.Keywords
This publication has 42 references indexed in Scilit:
- Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancerInternational Journal of Gynecological Cancer, 2024
- Alternative Tissue Fixation Protocols Dramatically Reduce the Impact of DNA Artifacts, Unraveling the Interpretation of Clinical Comprehensive Genomic ProfilingLaboratory Investigation, 2023
- Characteristics of molecular classification in 52 endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatmentGynecology and Obstetrics Clinical Medicine, 2023
- Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasiaPathology - Research and Practice, 2022
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Mismatch repair status influences response to fertility-sparing treatment of endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2021
- Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer ConsortiumInternational Journal of Cancer, 2020
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancerCancer, 2017
- Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysisAmerican Journal of Obstetrics and Gynecology, 2012
- Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: Case series and literature reviewTaiwanese Journal of Obstetrics and Gynecology, 2011